In our study, we combined HD + HP once every two weeks for 6 times (3
months), in which HD + HP was completed within the first 2 hours of treatment, followed
by 3 hours of conventional HD. The study was done on regular hemodialysis patients
currently going through 2 times per week sessions. This study is designed to measure
effects of HD + HP combination on β2-microglobulin concentration, quality of life scored
with SF-36 and hope of life scored with BIA phase angle parameter, of regular
hemodialysis patients. Besides that, we also correlate β2-microglobulin concentration
with quality of life and hope of life parameters. Lastly, we measure the effects of HD +
HP on subjective complains and side effects that might appear during HD + HP
treatment. After the sixth trial, we found that the combination of HD + HP decreases β2-
microglobulin significantly by 20.07%, although it is still higher than normal range.
Several factors that lead to the result may be use of low-flux dialyzer, reuse of dialyzer,
prolonged space between each treatment that saw accumulation of β2-microglobulin
again, as well as the short stint of overall study of just 3 months. We also found
significant increase in quality of life score, in terms of physical health (36.46 ± 8.98 vs
46.90 ± 7.04) and mental health (45.95 ± 11.10 vs 55.22 ± 6.29). Hope of life parameter
also increase with increase in phase angle measurement (5.25 ± 1.98 vs 5.63 ± 2.42),
although statistically it is not significant. Increase in quality of life measurement and
hope of life parameter after HD + HP followed normal population pattern. This shows
that combination of HD + HP decreases β2M serum and increase patient’s quality of life.